Bank of America Corp DE Buys 53,336 Shares of Monopar Therapeutics Inc. $MNPR

Key Points

• Bank of America increased its Monopar Therapeutics stake by 838.2% in the first quarter, purchasing 53,336 shares and ending with 59,699 shares valued at approximately $3.27 million.
• MNPR shares opened at $111.89, near their 12-month high of $124.82, while the company reported a quarterly loss of $0.62 per share—slightly better than analysts’ expectations.
• Analyst sentiment remains a “Moderate Buy,” with a consensus price target of $118.67, although company directors recently sold shares under pre-arranged trading plans.

Bank of America Corp DE boosted its stake in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 838.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,699 shares of the company's stock after buying an additional 53,336 shares during the quarter. Bank of America Corp DE owned approximately 0.89% of Monopar Therapeutics worth $3,271,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets increased its holdings in shares of Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock worth $57,000 after buying an additional 349 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth approximately $65,000. JPMorgan Chase & Co. raised its stake in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after acquiring an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Monopar Therapeutics in the second quarter valued at approximately $80,000. 1.83% of the stock is currently owned by institutional investors.

Monopar Therapeutics Price Performance

Shares of MNPR stock opened at $111.89 on Monday. The firm has a market cap of $750.78 million, a price-to-earnings ratio of -51.56 and a beta of 1.47. Monopar Therapeutics Inc. has a 12 month low of $32.77 and a 12 month high of $124.82. The stock has a 50-day moving average price of $106.44 and a 200 day moving average price of $75.12.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. Sell-side analysts predict that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 4,090 shares of Monopar Therapeutics stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total transaction of $455,585.10. Following the completion of the sale, the director owned 7,396 shares of the company's stock, valued at approximately $823,840.44. The trade was a 35.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Raymond Anderson sold 3,142 shares of the company's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the sale, the director owned 23,751 shares of the company's stock, valued at $2,654,649.27. The trade was a 11.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on MNPR shares. Zacks Research lowered Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 13th. Cantor Fitzgerald downgraded Monopar Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. BTIG Research boosted their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Monopar Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $118.67.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source